Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens

被引：37

作者：

Klemis, Verena ^{[1
]}

Schmidt, Tina ^{[1
]}

Schub, David ^{[1
]}

Mihm, Janine ^{[2
,5
]}

Marx, Stefanie ^{[1
]}

Abu-Omar, Amina ^{[1
]}

Ziegler, Laura ^{[1
]}

Hielscher, Franziska ^{[1
]}

Guckelmus, Candida ^{[1
]}

Urschel, Rebecca ^{[1
]}

Wagenpfeil, Stefan ^{[3
]}

Schneitler, Sophie ^{[4
]}

Becker, Soeren L. ^{[4
]}

Gaertner, Barbara C. ^{[4
]}

Sester, Urban ^{[2
,5
]}

Sester, Martina ^{[1
]}

机构：

[1] Saarland Univ, Dept Transplant & Infect Immunol, Homburg, Germany

[2] Saarland Univ, Dept Internal Med 4, Homburg, Germany

[3] Saarland Univ, Inst Med Stat Epidemiol & Med Informat, Campus Homburg Saar, Homburg, Germany

[4] Saarland Univ, Inst Med Microbiol & Hyg, D-66421 Homburg, Germany

[5] SHG Kliniken, Volklingen, Germany

来源：

NATURE COMMUNICATIONS | 2022年 / 13卷 / 01期

关键词：

CHADOX1; NCOV-19; MESSENGER-RNA; PHASE-2; SAFETY;

D O I：

10.1038/s41467-022-32321-0

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Comparative analyses of the immunogenicity and reactogenicity of homologous and heterologous SARS-CoV-2 vaccine-regimens will inform optimized vaccine strategies. Here we analyze the humoral and cellular immune response following heterologous and homologous vaccination strategies in a convenience cohort of 331 healthy individuals. All regimens induce immunity to the vaccine antigen. Immunity after vaccination with ChAdOx1-nCoV-19 followed by either BNT162b2 (n = 66) or mRNA-1273 (n = 101) is equivalent to or more pronounced than homologous mRNA-regimens (n = 43 BNT162b2, n = 59 mRNA-1273) or homologous ChAdOx1-nCoV-19 vaccination (n = 62). We note highest levels of spike-specific CD8 T-cells following both heterologous regimens. Among mRNA-containing combinations, spike-specific CD4 T-cell levels in regimens including mRNA-1273 are higher than respective combinations with BNT162b2. Polyfunctional T-cell levels are highest in regimens based on ChAdOx1-nCoV-19-priming. All five regimens are well tolerated with most pronounced reactogenicity upon ChAdOx1-nCoV-19-priming, and ChAdOx1-nCoV-19/mRNA-1273-boosting. In conclusion, we present comparative analyses of immunogenicity and reactogenicity for heterologous vector/mRNA-boosting and homologous mRNA-regimens.

引用

页数：11

共 38 条

[1] Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants [J].

Abu-Raddad, Laith J. ;

Chemaitelly, Hiam ;

Butt, Adeel A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (02) :187-189

[2]

Agermose Gram M, MEDRXIV, DOI [10.1101/2021.07.26.21261130v1(2021), DOI 10.1101/2021.07.26.21261130V1(2021)]

[3] Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine [J].

Baden, Lindsey R. ;

El Sahly, Hana M. ;

Essink, Brandon ;

Kotloff, Karen ;

Frey, Sharon ;

Novak, Rick ;

Diemert, David ;

Spector, Stephen A. ;

Rouphael, Nadine ;

Creech, C. Buddy ;

McGettigan, John ;

Khetan, Shishir ;

Segall, Nathan ;

Solis, Joel ;

Brosz, Adam ;

Fierro, Carlos ;

Schwartz, Howard ;

Neuzil, Kathleen ;

Corey, Larry ;

Gilbert, Peter ;

Janes, Holly ;

Follmann, Dean ;

Marovich, Mary ;

Mascola, John ;

Polakowski, Laura ;

Ledgerwood, Julie ;

Graham, Barney S. ;

Bennett, Hamilton ;

Pajon, Rolando ;

Knightly, Conor ;

Leav, Brett ;

Deng, Weiping ;

Zhou, Honghong ;

Han, Shu ;

Ivarsson, Melanie ;

Miller, Jacqueline ;

Zaks, Tal .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) :403-416

[4] SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination [J].

Behrens, Georg M. N. ;

Cossmann, Anne ;

Stankov, Metodi V. ;

Nehlmeier, Inga ;

Kempf, Amy ;

Hoffmann, Markus ;

Poehlmann, Stefan .

LANCET, 2021, 398 (10305) :1041-1042

[5] Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant [J].

Bernal, Jamie Lopez ;

Andrews, Nick ;

Gower, Charlotte ;

Gallagher, Eileen ;

Simmons, Ruth ;

Thelwall, Simon ;

Stowe, Julia ;

Tessier, Elise ;

Groves, Natalie ;

Dabrera, Gavin ;

Myers, Richard ;

Campbell, Colin N. J. ;

Amirthalingam, Gayatri ;

Edmunds, Matt ;

Zambon, Maria ;

Brown, Kevin E. ;

Hopkins, Susan ;

Chand, Meera ;

Ramsay, Mary .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (07) :585-594

[6] Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial [J].

Borobia, Alberto M. ;

Carcas, Antonio J. ;

Perez-Olmeda, Mayte ;

Castano, Luis ;

Jesus Bertran, Maria ;

Garcia-Perez, Javier ;

Campins, Magdalena ;

Portoles, Antonio ;

Gonzalez-Perez, Maria ;

Garcia Morales, Maria Teresa ;

Arana-Arri, Eunate ;

Aldea, Marta ;

Diez-Fuertes, Francisco ;

Fuentes, Inmaculada ;

Ascaso, Ana ;

Lora, David ;

Imaz-Ayo, Natale ;

Baron-Mira, Lourdes E. ;

Agusti, Antonia ;

Perez-Ingidua, Carla ;

Gomez de la Camara, Agustin ;

Ramon Arribas, Jose ;

Ochando, Jordi ;

Alcami, Jose ;

Belda-Iniesta, Cristobal ;

Frias, Jesus .

LANCET, 2021, 398 (10295) :121-130

[7] mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar [J].

Chemaitelly, Hiam ;

Yassine, Hadi M. ;

Benslimane, Fatiha M. ;

Al Khatib, Hebah A. ;

Tang, Patrick ;

Hasan, Mohammad R. ;

Malek, Joel A. ;

Coyle, Peter ;

Ayoub, Houssein H. ;

Al Kanaani, Zaina ;

Al Kuwari, Einas ;

Jeremijenko, Andrew ;

Kaleeckal, Anvar Hassan ;

Latif, Ali Nizar ;

Shaik, Riyazuddin Mohammad ;

Abdul Rahim, Hanan F. ;

Nasrallah, Gheyath K. ;

Al Kuwari, Mohamed Ghaith ;

Al Romaihi, Hamad Eid ;

Al-Thani, Mohamed H. ;

Al Khal, Abdullatif ;

Butt, Adeel A. ;

Bertollini, Roberto ;

Abu-Raddad, Laith J. .

NATURE MEDICINE, 2021, 27 (09) :1614-+

[8] Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study [J].

Chung, Hannah ;

He, Siyi ;

Nasreen, Sharifa ;

Sundaram, Maria E. ;

Buchan, Sarah A. ;

Wilson, Sarah E. ;

Chen, Branson ;

Calzavara, Andrew ;

Fell, Deshayne B. ;

Austin, Peter C. ;

Wilson, Kumanan ;

Schwartz, Kevin L. ;

Brown, Kevin A. ;

Gubbay, Jonathan B. ;

Basta, Nicole E. ;

Mahmud, Salaheddin M. ;

Righolt, Christiaan H. ;

Svenson, Lawrence W. ;

MacDonald, Shannon E. ;

Janjua, Naveed Z. ;

Tadrous, Mina ;

Kwong, Jeffrey C. .

BMJ-BRITISH MEDICAL JOURNAL, 2021, 374

[9] Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study [J].

Costa Clemens, Sue Ann ;

Weckx, Lily ;

Clemens, Ralf ;

Almeida Mendes, Ana Verena ;

Souza, Alessandra Ramos ;

Silveira, Mariana B., V ;

Farias da Guarda, Suzete Nascimento ;

de Nobrega, Maristela Miyamoto ;

de Moraes Pinto, Maria Isabel ;

Gonzalez, Isabela G. S. ;

Salvador, Natalia ;

Franco, Marilia Miranda ;

de Avila Mendonca, Renata Navis ;

Queiroz Oliveira, Isabelle Silva ;

de Freitas Souza, Bruno Solano ;

Fraga, Mayara ;

Aley, Parvinder ;

Bibi, Sagida ;

Cantrell, Liberty ;

Dejnirattisai, Wanwisa ;

Liu, Xinxue ;

Mongkolsapaya, Juthathip ;

Supasa, Piyada ;

Screaton, Gavin R. ;

Lambe, Teresa ;

Voysey, Merryn ;

Pollard, Andrew J. .

LANCET, 2022, 399 (10324) :521-529

[10] BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting [J].

Dagan, Noa ;

Barda, Noam ;

Kepten, Eldad ;

Miron, Oren ;

Perchik, Shay ;

Katz, Mark A. ;

Hernan, Miguel A. ;

Lipsitch, Marc ;

Reis, Ben ;

Balicer, Ran D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (15) :1412-1423

← 1 2 3 4 →